| Oct 10 |
Rigel Pharmaceuticals: Looking For More Growth
|
| Oct 10 |
Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships
|
| Sep 12 |
Rigel to Present at the 2024 Cantor Global Healthcare Conference
|
| Sep 3 |
Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan
|
| Aug 29 |
With 45% stake, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) seems to have captured institutional investors' interest
|
| Aug 29 |
Rigel to Participate in Upcoming September Investor Conferences
|
| Aug 9 |
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2024 Earnings Call Transcript
|
| Aug 7 |
Q2 2024 Rigel Pharmaceuticals Inc Earnings Call
|
| Aug 6 |
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 6 |
Rigel Pharmaceuticals GAAP EPS of -$0.06 beats by $0.14, revenue of $36.84M beats by $3.14M
|
